Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00081471 · ClinicalTrials.gov registry record · Phase 3
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
A Phase 3 study of Anemia, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 324
- Enrollment target
- 20
- Study locations
NCT00081471: Completed Phase 3 study of Anemia, sponsored by Hoffmann-La Roche.
NCT00081471 is a Phase 3 study of Anemia that has completed, run by Hoffmann-La Roche. The registered enrollment target is 324 participants, below the 423-participant average among 72 other Anemia trials with a reported enrollment target (23% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00081471, a Phase 3 study of Anemia, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 324 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the efficacy and safety of subcutaneous Mircera in the treatment of renal anemia in patients with chronic kidney disease who are not on dialysis and not receiving epoetin or any other erythropoietic substance. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.
Conditions Studied
Interventions
- DRUG darbepoetin alfa
- DRUG methoxy polyethylene glycol-epoetin beta [Mircera]
Study Locations (20)
California
- - Los Angeles
- - Mather
- - Stanford
Texas
- - Austin
- - Dallas
- - Houston
Florida
- - Bay Pines
- - Ocala
Massachusetts
- - Boston
- - Boston
Connecticut
- - Stamford
Louisiana
- - Shreveport
Michigan
- - Detroit
New York
- - Flushing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 324 participants |
| Start Date | 2004-06 |
| Est. Completion | 2006-07 |
| Phase | Phase 3 |
What the finished NCT00081471 record still lists
NCT00081471 is an interventional study that assigns participants to a tested intervention. The registered 324 participants enrollment target is mid-sized for trials with a published cap, below the 423-participant average among 72 other Anemia trials with a reported enrollment target (23% lower).
The record links to 1 condition, with Anemia appearing as the primary indexed condition, and to 2 interventions - of which darbepoetin alfa is the first listed.
NCT00081471 names 20 study sites across 14 states, led by California, Texas, Florida.
Frequently Asked Questions
What is clinical trial NCT00081471 about?
NCT00081471 is a clinical study titled "A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis". This study will assess the efficacy and safety of subcutaneous Mircera in the treatment of renal anemia in patients with chronic kidney disease who are not on dialysis and not receiving epoetin or any other erythropoietic substance. The anticipated time on study treatment is 1-2 years and the target...
What is the current status of trial NCT00081471?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 324 participants. The study started on 2004-06. Estimated completion is 2006-07.
What conditions does trial NCT00081471 study?
This clinical trial studies the following conditions: Anemia.
What interventions are being tested in trial NCT00081471?
The interventions under investigation include: darbepoetin alfa (DRUG), methoxy polyethylene glycol-epoetin beta [Mircera] (DRUG).
Who is sponsoring clinical trial NCT00081471?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00081471 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00081471's enrollment target sits among peer trials
324 21st of 72 higher than 51 of 72 other Anemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
RECRUITING · Phase 3
-
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
ACTIVE NOT RECRUITING · Phase 3
-
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ACTIVE NOT RECRUITING · Phase 3
-
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
ACTIVE NOT RECRUITING · Phase 3
-
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04164173 · 324 participants · NA
Hyperinflation Respiratory Therapies in Cardiac Surgery Patients
- NCT04708054 · 324 participants · Phase 2
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- NCT05261399 · 324 participants · Phase 3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
- NCT05353322 · 324 participants · NA
Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia